Approval · Notice of Compliance 37459 · 2026
XYDALBA: Notice of Compliance 37459
Issued May 1, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37459
- Date
- May 1, 2026
- Company
- Knight Therapeutics Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Administrative: Change in product ownership
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| XYDALBA | 02480522 | Marketed |
Medicinal ingredients
- DALBAVANCIN HYDROCHLORIDE 500 MG per VIAL